Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Acquisitions (2017 - 2019)

IGC Pharma (IGC) has disclosed Acquisitions for 8 consecutive years, with $19000.0 as the latest value for Q3 2019.

  • Quarterly Acquisitions rose 137.5% to $19000.0 in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $55000.0 through Sep 2019, up 193.22% year-over-year, with the annual reading at $45000.0 for FY2019, 30.77% down from the prior year.
  • Acquisitions for Q3 2019 was $19000.0 at IGC Pharma, up from $4000.0 in the prior quarter.
  • The five-year high for Acquisitions was $149000.0 in Q4 2017, with the low at -$221000.0 in Q1 2018.
  • Average Acquisitions over 5 years is $146.17, with a median of $4500.0 recorded in 2018.
  • The sharpest move saw Acquisitions tumbled 3862.56% in 2016, then skyrocketed 137.5% in 2019.
  • Over 5 years, Acquisitions stood at -$414.0 in 2015, then crashed by 3862.56% to -$16405.0 in 2016, then skyrocketed by 1008.26% to $149000.0 in 2017, then crashed by 80.54% to $29000.0 in 2018, then crashed by 34.48% to $19000.0 in 2019.
  • According to Business Quant data, Acquisitions over the past three periods came in at $19000.0, $4000.0, and $3000.0 for Q3 2019, Q2 2019, and Q1 2019 respectively.